Zhengye Biotechnology Holding Limited · NASDAQ:ZYBT
Zhengye Biotechnology — Investor Presentation (May 2026)
27 slides from Zhengye Biotechnology's investor presentation, May 22, 2026
Slide 1: Zhengye Biotechnology Holding Limited Investor Presentation
Zhengye Biotechnology Holding Limited Nasdaq Ticker: ZYBT Investor Presentation
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains forward-looking statements that reflect our current expectations and views of future events, all of which are subject to risks and uncertainties. Forward-looking statements give our current expectations or forecasts of future events. You can ident
Slide 3: Equity Snapshot
Equity Snapshot Ticker Symbol ZYBT Share Price*(5/21/26) $0.87 52 Week Range*(5/21/26) $0.68-$13.08 Market Capitalization*(5/21/26) $41.23 million Shares Outstanding*(5/21/26) 47.39 million Revenue (FY2025) $16.6 million Fiscal Year End December 31 Source: * Yahoo Finance 3
Slide 4: Content
Content 01 Company and Business Overview 02 Industry Overview 03 Growth Strategies 04 Financial Highlights
Slide 5: Company Overview
Company Overview We focus on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. We market a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. ~20 50 29 years in enhancing veterinary v
Slide 6: Company Overview
Company Overview Our mission is to become a world-leading manufacturer and distributor of veterinary vaccines 3 1 GMP veterinary vaccine quality examination center production floors 13 1 GMP vaccine production independent R&D center lines 6
Slide 7: The Production Process
The Production Process We produce products and stock inventory of raw materials at the facilities, based on market demand, orders it receives/plans to receive, production plan and capacity, and procurement information from distributors. • Sales department receives orders • Purchasing department purc
Slide 8: Investment Highlights
Investment Highlights 1 2 3 4 5 High Production Quality Extensive Distribution Channels and Quality Control 50 Diversified Strong Research and Experienced Products Development Capabilities Management Team and Employees 8
Slide 9: Diversified Products – Commercialized Products
Diversified Products – Commercialized Products 19 Swine vaccines 21 Poultry vaccines Products Portfolio 44 Veterinary Vaccines 5 Bovine and Ovine vaccines 1 Pet vaccine 9
Slide 10: Diversified Products – Commercialized Products
Diversified Products – Commercialized Products Products Portfolio 44 Veterinary Vaccines 10
Slide 11: New Product Development Process
New Product Development Process New veterinary drug development is a lengthy process (5-10 years) Conformity Certification of New Lab investigation Inspection Veterinary Drugs Application for Serial No. Pilot Production Registration of New Assignment Veterinary Drugs Clinical Trial Clinical Trial Co
Slide 12: High Production Quality - By GMP & ISO
High Production Quality- By GMP & ISO Quality Control Management System The Whole Process of Examinations Standards Manufacturing Physical property inspection • the appearance Raw Materials and • properties • dosage form Viral Seeds Inspection • color • other aspects of the product comply with the q
Slide 13: Strong R&D Capabilities – Independent R&D
Strong R&D Capabilities – Independent R&D • Own 1 research center, which collectively has helped the operating entity develop dozens of vaccines, inventions, and utility models. • Have 51 experienced experts work for our R&D department with Research Center glory achievements and awards. • Developed
Slide 14: Strong R&D Capabilities - Cooperative R&D
Strong R&D Capabilities - Cooperative R&D • Maintained long-term cooperative relationships with universities and institutions: - Universities and research institutes - early-stage basic research - Our R&D - basic research, pilot study and industrialization research • Licensed to use vaccine producti
Slide 15: Extensive Distribution Channels
Extensive Distribution Channels Revenue Breakdown Direct Sales Channel – 44.6% * By Distribution Channel * • Participating tender and procurement of major breeding companies • 98* direct end-user customers • Major customer includes the world’s largest breeding company, Muyuan Foods Co., Ltd. (002714
Slide 16: Experienced Management Team and Employees
Experienced Management Team and Employees Zhenfa Han Aiden Han Songlin Song Ping Wang Zhongyao Liu Director & Chairman of the Board Co-Chief Executive Officer Co-Chief Executive Officer Chief Financial Officer Chief Operating Officer Director of our operating entity since • Co-Chief Executive Office
Slide 17: Experienced Management Team and Employees
Experienced Management Team and Employees Wei Lian Yuhong Cheng Vice General Manager Vice General Manager Veterinarian Professionals with more than Multidisciplinary Professionals with more 19 years of industry experience than 26 years of management experience •Vice General Manager since May 2023. •
Slide 18: Content
Content 01 Company and Business Overview 02 Industry Overview 03 Growth Strategies 04 Financial Highlights
Slide 19: Industry Overview
Industry Overview Historical and Forecasted Market Size of Veterinary Vaccine in China, Ranking of Revenue of China’s Veterinary Vaccine Companies (2) 2019-2026E (1) RMB Billion, 2022 Period CAGR 2019-2022 16.0% 1.5 2022-2026E 6.5% 1.4 3.2 US$ Billion 2.9 3.0 1.2 2.7 2.5 2.5 1.0 2.2 1.0 1.6 0.9 0.8
Slide 20: Industry Overview
Industry Overview Historical and Forecasted Market Size of Swine Vaccine in China, Historical and Forecasted Market Size of Poultry Vaccine in China, 2019-2026E 2019-2026E Period CAGR Period CAGR 2019-2022 28.9% 2019-2022 3.5% 2022-2026E 4.9% 2022-2026E 6.6% 1.39 1.45 US$ Billion US$ Billion 1.33 1.
Slide 21: Industry Overview
Industry Overview Historical and Forecasted Market Size of Bovine and Ovine Vaccine in China, Historical and Forecasted Market Size of Pet and Other Vaccine in China, 2019-2026E 2019-2026E * US$ Billion Period CAGR US$ Billion Period CAGR 2019-2022 13.2% 2019-2022 18.6% 2022-2026E 7.8% 2022-2026E 23
Slide 22: Content
Content 01 Company and Business Overview 02 Industry Overview 03 Growth Strategies 04 Financial Highlights
Slide 23: Growth Strategies
Growth Strategies Develop high-demand products and expand business by entering household animal vaccines industry 01 • Plan to develop Subunit Vaccine of Porcine Circovirus Type 2 (Recombinant Baculovirus Strain OKM) and other high-demand products • Plan to develop and manufacture vaccines for compa
Slide 24: Content
Content 01 Company and Business Overview 02 Industry Overview 03 Growth Strategies 04 Financial Highlights
Slide 25: Financial Highlights
Financial Highlights Revenue Revenue Breakdown by Products US$ Million $25.5 11.8% 8.3% 7.0% 10.7% $16.6 77.5% 84.7% FY2024 FY2025 FY2024 FY2025 Swine vaccines Poultry vaccines Other vaccines Note: Fiscal year ended December 31. 25
Slide 26: Financial Highlights
Financial Highlights Gross Profit and Gross Profit Margin Net Income (Loss) US$ Million Gross profit margin US$ Million 49.0% $1.8 20.5% $12.5 FY2024 FY2025 $3.4 $(11.9) FY2024 FY2025 Note: Fiscal year ended December 31. 26
Slide 27: Contact
Contact Zhengye Biotechnology Holding Limited Email: ir@jlzybio.com Tel: +86-0432-63047008 Address: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, China 27
Zhengye Biotechnology Holding — Investor Presentation (May 2026) on 6ix